

# Weekly COVID-19 Breakthrough Infections Report

**Clark County, Nevada** 


# Date: October 28, 2021

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.


Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.



## Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overa	
		%
All	11104 1	00
Age (in years)		
5-17	209	2
18-24	670	6
25-49	4729	43
50-64	2831	25
65+	2665	24
Gender		
Male	4999	45
Female	6046	54
Unknown	59	1
Race/Ethnicity		
Hispanic	2120	19
White	4291	39
Black	763	7
API	1234	11
AEA	18	0
Other	511	5
Unknown	2167	20
Travel History		
Yes	963	9
No	4987	45
Unknown	5154	46
Hospitalization		
Yes	566	5
No	5858	53
Unknown	4680	42
Death		
Yes	183	2
No	1841	17
Unknown	9080	82
Vaccine Type		
Pfizer	8180	74
Unknown	82	1
Moderna	2833	26
Janssen	9	0
Underlying Conditions		
Yes	2840	26
No	8264	74

## Table 1: Population Characteristics of COVID-19 Breakthrough Cases

#### Table 2: Breakthrough Case Rates

Fully Vaccinated	Vaccinated	Unvaccinated	Unvaccinated	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate
Population*	Cases	Population	Cases		per 100K population
1117221	11104	1200953	320003	994	26646

\* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson \$ Janssen vaccine.



	Overa	1
	N %	
All	566 10	0
Age (in years)		
18-24	3	1
25-49	45	8
50-64	91 1	6
65+	427 7	5
Gender		
Male	328 5	8
Female	237 4	2
Unknown	1	0
Race/Ethnicity		
Hispanic	74 1	3
White	327 5	8
Black	67 1	2
API	45	8
AEA	1	0
Other	17	3
Unknown	35	6
Travel History		
Yes	32	6
No	297 5	2
Unknown	237 4	2
Death		
Yes	160 2	8
No	106 1	9
Unknown	300 5	3
Vaccine Type		
Pfizer	385 6	8
Unknown	11	2
Moderna	169 3	0
Janssen	1	0
Underlying Conditions		
Yes	369 6	5
No	197 3	5

# Table 3: Population Characteristics of COVID-19 Breakthrough Hospitalizations

# Table 4: Variants of Concern (VOC) among Breakthrough cases, hospitalizations and deaths

Variants of concern (VOC)	Breakthrough Cases	Percent(%) of Breakthrough Cases	Breakthrough Hospitalizations	Percent(%) of Breakthrough Hospitalizations	Breakthrough Deaths	Percent(%) of Breakthrough Deaths
Alpha	36	4	1	3	1	8
Delta	846	94	30	91	11	85
Epsilon	4	0	2	6	1	8
Gamma	15	2				

\* Please note that only limited number of specimens are sent for sequencing of VOCs compared to total number of COVID-19 cases/breakthrough cases.



	Ove	Overall	
	Ν	%	
All	183	100	
Age (in years)			
25-49	7	4	
50-64	16	9	
65+	160	87	
Gender			
Male	115	63	
Female	68	37	
Race/Ethnicity			
Hispanic	21	11	
White	127	69	
Black	21	11	
API	10	5	
AEA	1	1	
Unknown	3	2	
Variant of concern (VOC)			
Epsilon	1	1	
Delta	11	6	
Alpha	1	1	
Unknown	170	93	
Hospitalization			
Yes	160	87	
No	6	3	
Unknown	17	9	
Vaccine Type			
Pfizer	135	74	
Unknown	3	2	
Moderna	45	25	
Underlying Conditions			
Yes	96	52	
No	87	48	

# Table 5: Population Characteristics of COVID-19 Breakthrough Deaths

# **Table 5: Breakthrough Death Rates**

Fully Vaccinated Population	Vaccinated Deaths	Unvaccinated Population	Unvaccinated Deaths	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate per 100K population
1117221	183	1200953	5780	16	481

\* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson \$ Janssen vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	369	65
	No	197	35
Hypertension	Yes	218	N/A
Immunocompromised	Yes	26	N/A
Chronic Heart Disease	Yes	114	N/A
Chronic Liver Disease	Yes	11	N/A
Chronic Kidney Disease	Yes	66	N/A
Diabetes	Yes	142	N/A
Neurologic/Neurodevelopmental	Yes	38	N/A
Chronic Lung Disease	Yes	96	N/A
Historically Healthy	Yes	51	N/A

## Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

### Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	96	52
	No	87	48
Hypertension	Yes	65	N/A
Immunocompromised	Yes	10	N/A
Chronic Heart Disease	Yes	31	N/A
Chronic Liver Disease	Yes	2	N/A
Chronic Kidney Disease	Yes	23	N/A
Diabetes	Yes	38	N/A
Neurologic/Neurodevelopmental	Yes	10	N/A
Chronic Lung Disease	Yes	24	N/A
Historically Healthy	Yes	4	N/A

Notes:

\* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

\* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

\* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).